Brainsway Ltd. Partners with Neurolief for Strategic Investment in Proliv™Rx System Launch for Major Depressive Disorder
I'm PortAI, I can summarize articles.
Brainsway Ltd. has partnered with Neurolief to invest strategically in the launch of the Proliv™Rx system for treating Major Depressive Disorder. This collaboration aims to utilize Brainsway's commercial expertise to support Neurolief's FDA approval process and the scaling of its innovative at-home treatment solution. Both companies focus on enhancing access to non-invasive mental health treatments for patients unresponsive to traditional therapies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments